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Over 3.2 million children worldwide are infected with HIV, but only 24% of these children receive antiretroviral therapy (ART).
ART adherence among children is a crucial part of managing human-immunodeficiency virus (HIV) infection and extending the
life and health of infected children. Important causes of poor adherence are formulation- and regimen-specific properties, including
poor palatability, large pill burden, short dosing intervals, and the complex storage and transportation of drugs. This review aims
to summarize the various regimen- and formulation-based barriers to ART adherence among children to support the need for
new and innovative pediatric formulations for antiretroviral therapy (ART). Detailing the arguments both for and against investing
in the development of pediatric HIV medications, as well as highlighting recent advances in pediatric ART formulation research,
provides a synopsis of the current data related to pediatric ART formulations and adherence.
1. Background
Over 3.2 million children worldwide are infected with HIV,
but only 24% of these children are on the antiretroviral
therapy (ART) they need [1]. Ninety percent of children living
with HIV reside in sub-Saharan Africa, and HIV/AIDS is
the most common cause of death for adolescents in Africa
and the second most common cause of death for adolescents
worldwide [2]. At the 2015 United Nations’ Summit, the
World Health Organization (WHO) lifted age and medical
restrictions for ART initiation [3]. The WHO now recom-
mends that all individuals who are infected with HIV should
start ART immediately,making all populations and ages eligi-
ble for treatment. AllHIV-exposed infants should also receive
a regimen for ARTmeant for prophylaxis. As these guidelines
are implemented and access to ART for children scales up
worldwide, manymore infants, children, and adolescents will
be taking antiretroviral medications.
Adherence to ART is crucial to HIVmanagement. Proper
adherence to ART leads to lower viral loads, decreased
symptoms in patients, and decreased viral resistance [4].
Viral resistance to first-line ART requires patients to switch
to more expensive and less available second- and third-
line therapies. As ART becomes more potent, it improves
the immunological response for HIV-infected children, thus
extending their life expectancy. With good ART adherence,
HIV-infected children can live long, healthy lives; therefore,
it becomes a priority to study and address the causes of poor
adherence with the goal of maintaining successful therapy for
as long as possible during a child’s lifelong treatment.
Many barriers prevent children with HIV frommaintain-
ing good adherence.These include cost ofmedications, access
to medications, stigma associated with HIV, and disclosure
of HIV to children [5, 6]. However, an underlying theme
within the barriers to ART adherence studies is the lack of
pediatric-friendly formulations. Current pediatric ARTs are
often unpalatable to children of all ages [7]. All these factors
influence adherence and, therefore, survival of children with
HIV.
Developing child-friendly formulations of ARTwillmake
it easier for caregivers to administer medications to children
and easier for children to take medications. Both strate-
gies will increase adherence, which is critical to successful
long-term HIV therapy. This paper will review the cur-
rent obstacles preventing adherence to pediatric ART, the
barriers to creating more acceptable pediatric formulations,
and evidence supporting the need for appropriate pediatric
formulations of ART.
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2. Four Main Obstacles Preventing Adherence
to Current Pediatric Antiretroviral Therapy
2.1. Palatability. Poor palatability is directly associated with
poor adherence in children with HIV [8–10]. Studies report
that caregivers have difficulty administering medication to
children due to the bitter taste of the medications [11, 12].
Poor palatability creates a struggle between children and their
caregivers, frequently causing caregivers to take on the role of
persuasive diplomats during medication administration [13].
This struggle adds to the burden that caregivers experience
when providing care to their HIV-infected children. One
study found that 81% of caregivers identified better tasting
medications as the most important innovation needed to
increase adherence [14].
The World Health Organization recommends lopinavir/
ritonavir (LVP/r) as the first-line ART to initiate in children
three years of age and younger and recommended it as the
second-line treatment for children three years of age and
older [15]. Protease inhibitors (PIs), such as lopinavir and
ritonavir, are clinically effective in young children, and
many are available in liquid forms, which eases dosing in
children who are unable to swallow tablets [16]. However,
poor palatability prevents PIs from having optimal benefits
in HIV-infected children. Many studies describe the bitter
taste associated with protease inhibitors such as LVP/r [17–
19]. This bitter taste has been found to impact adherence in
young children, leading many authors to call for new and
innovative ways to administer PIs [20–22]. Developing more
child-friendly formulations of protease inhibitors, particu-
larly formulations that taste reasonably well, is a crucial need
for children living with HIV.
2.2. Regimen Complexity. In addition to poor palatability,
large pill burden has also been found to decrease adherence
to ART [23, 24]. Many children have to take three or more
pills or a combination of pills and liquids, every day, twice a
day. The advent of fixed-dose combinations (FDCs), which
combine two or three antiretroviral medications into one
pill, has been shown to increase adherence in older children
who are able to swallow pills [25, 26]. Few FDCs exist in
nonpill form, therefore limiting their administration to older
children who are able to swallow large pills [27].
In addition to FDCs, other ways of simplifying dosing
regimens, such as once-a-day formulations, have also been
shown to positively affect medication compliance. A study
of extended-release, nevirapine-based ART, which can be
given once a day, showed good immunologic response and
improved adherence in children [28]. These formulations
significantly increase dosing intervals, while simultaneously
decreasing the hassle of medication administration for care-
givers. The once-a-day formulations have been found to be
preferable to FDCs and liquids [24]. It is therefore important
to strive for FDCs that can be safely administrated once a
day to children as a way to simplify ART administration and
decrease pill burden.
Liquid formulations of ART were originally created
for infants and children with HIV to ease administration
by caregivers. Young children are not generally physically
capable of safely swallowing pills or tablets. Nonetheless,
liquid formulations have many shortcomings of their own. In
addition to the poor palatability of liquid ARTs, they often
require caregivers to measure out and administer precise
amounts of the liquid. This can be a challenge: one study
found that 80% of caregivers preferred tablets over liquids
due to the inability to measure accurate doses, easy spillage
during administration, and the large quantities they needed
to administer [9]. Many liquid formulations also require
refrigeration, which can become a huge problem in resource-
limited settings where electricity is not always available in
patients’ homes. In the current WHO requirements, for
children under three years of age, three separate liquid med-
ications must be measured and administered daily based on
weight, presenting no small challenge for their caregivers [15].
2.3. Swallowing. Because of the aforementioned complexity
of liquids, caregivers often switch to pills as early as possible.
However, many studies have found swallowing pills to be
a barrier to adherence in children [10, 29, 30]. Studies
have recorded how caregivers take measures into their own
hands to overcome these challenges, documenting that they
open capsules, crush tablets, and sprinkle contents into food
[31, 32]. Crushing pills or opening capsules can reduce the
bioavailability of the ART because the entire contents may
not be administered, thus significantly reducing the targeted
therapeutic exposure [30]. This may reduce viral suppression
and promote viral resistance.
Many studies have looked into alternatives to swallowing
large pills for children with HIV. Potential innovations to
decrease the struggle between caregivers and their children
include the following: recommendations to open capsules,
combining medications with food, and knowing which pills
are dispersible in water [33].
In another approach to this challenge, pill-swallowing
training for HIV-infected children has been shown to
increase ART adherence [19]. Gastrostomy tube insertion for
medication delivery is a more drastic and invasive solution
to administering ART to children who are unable to swallow
pills or liquids [34]. These examples all support the need
for easy-to-swallow medication options, such as sprinkles or
more palatable flavored liquids for young children, to increase
adherence to ART.
2.4. Storage and Transportation. A significant barrier to ART
compliance is the requirement for complex storage and
transportation.Many of the liquid protease inhibitors require
cold-chain storage. This requires both the clinic and the
patient to have a refrigerator to store the medications. In
resource-limited settings, such as sub-Saharan Africa, where
pediatric HIV is most prevalent, this might be an impossible
requirement [35].TheWorld Bank estimates that only 23% of
Kenyans, 18.2% of Ugandans, and 15.3% of Tanzanians have
access to electricity in their homes [36]. Often, caregivers
opt for tablet medications which they will crush or they
improperly store liquid formulations, both of which lower
bioavailability of the medications. A study reported that 63%
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of caregivers favored innovations of medications that did not
require refrigeration [14].
In addition, caregivers oftenmust transport large volumes
of liquid ART for their children to have a monthly supply
or more. This can be significant barrier for caregivers living
in rural areas who may walk many kilometers to arrive at
the clinic. For example, a 10 kg toddler on first-line ART
(ABC + 3TC + LVP/r) would take 28mL of ART daily, which
is equal to about two and a half liters every three months.
This requires caregivers to carry seventeen 160mL bottles
home from the clinic every three months. Due to the stigma
associated withHIV, caregivers aim to hidemedications from
their community, which is difficult when caregivers must
carry so many bottles. A study in Uganda found that 63% of
caregivers complained about the weight of bottles as being a
major barrier [37]. Large quantities of bottles or large bottles
are difficult to conceal and carry when traveling home from
the clinic, providing yet another reason why many caregivers
prefer to switch to tablets for their children as early as possible
[38]. It is therefore important to design HIV medication
formulations that are easy to transport and store.
3. Barriers to New Pediatric Formulations
3.1. Reducing Vertical Transmission Will Reduce New Cases of
Pediatric HIV. The world aims to eradicate mother-to-child
transmission of HIV, therefore eliminating child cases of HIV
and subsequently the need for pediatric formulations. This
may be seen to significantly reduce the impetus to develop
new pediatric ART formulations. Although the elimination
of pediatric HIV is a shared goal among healthcare providers,
pharmaceutical companies, and NGOs around the world, it
will takemany years before vertical transmission is prevented.
For now, millions of children are still living with this disease.
Until this objective is met, children need access to child-
friendly formulations of ART [39]. Moreover, a considerable
number of children are still unable to access these medica-
tions [40].
Many factors continue to drive the need for pediatric
ART, including the challenges of successfully implementing
PMTCT and scaling up widespread access to pediatric ART.
The risk of perinatal transmission remains at 2%, even
if a woman is on ART, has a low or undetectable viral
load, follows the recommended treatment regimen, and does
not breastfeed [41, 42]. Resource-limited settings, where
there is limited access to healthcare and baby formulas
are lacking, may not be able to even reduce their rates of
perinatal transmission to as low as 2% if they are not able
to address other challenges in healthcare delivery systems.
These challenges include a severe lack of healthcare workers,
poor implementation of appropriateHIV care and prevention
guidelines, and insufficient funds budgeted nationally for
healthcare [43, 44]. In addition, the WHO recommends
breastfeeding for all mothers, regardless of HIV status, with
mothers on ART throughout the breastfeeding period and
HIV-exposed infants on some ART for a portion of this time
[41]. Thus, both prevention efforts for HIV-exposed infants
and treatment for HIV-infected children continue to require
pediatric formulations to aid in the eradication of pediatric
HIV.
3.2. Inadequacies in Supply Chain and Healthcare Delivery
Systems. Surveys of the pediatric ART market review that
outdated procurement practices and gaps in supply chains
are often responsible for low uptake of innovative or new
pediatric drug formulations [40, 45, 46]. While some of these
gaps in access to the formulations are attributed to high
costs for new medications, other relevant barriers include
antiquated procurement practices and stagnant government
policies in the face of changing guidelines for treatment
[47, 48]. The introduction of effective pediatric ART inno-
vations will not make any impact on children’s health unless
these supply chain challenges are addressed and steps are
made to assess national barriers to uptake for particular
formulations, the level of education or acceptance around
new ART regimens, and country-level policies and practices
that will impact access and implementation. Incorporation
of innovative pediatric formulations into international and
national treatment guidelines and policies, such as the Essen-
tial Medicines WHO Model List, may assist in the scale-up
and stability of these treatment regimens [48]. At a national
level, Ministries of Health may need to work towards shaping
forward-looking, sustainable supply chain infrastructures
that can adapt to both changes in available therapy and in
healthcare system delivery [48].
3.3. Poor Incentives for Pediatric Formulation Development.
In its “Developing an Optimized List of Pediatric ARV
Formulations” report, the WHO presents the argument that
since children only make up 7% of HIV cases worldwide,
increases in the number of formulation options will decrease
the demand for currently available formulations. This could
lead to market instability and therefore a lack of incentive
for investment in the pediatric ART market [46]. On top
of this challenge is the previously discussed (and critically
important) global push to decrease the number of child HIV
infections and therefore to decrease the numbers of children
requiringART,which also takes away pharmaceutical compa-
nies’ incentive to pursue new options for children. Nonethe-
less, more than 3 million children will need to continue to
take ART even once the AIDS-free generation goals are met.
Incentives are required to drive further investment in
research and development for pediatric formulations and
innovations that have been shown to increase adherence.
Recognizing the potential lack of incentives for this work,
recent initiatives such as Drugs for Neglected Diseases
Initiative (DNDi), the NIH’s Development of Appropriate
Pediatric Formulations and Pediatric Drug Delivery Systems
RO1, and the Accelerating Children’s HIV/AIDS Treatment
(ACT) initiative supported by the Presidents Emergency Plan
for AIDS Relief (PEPFAR) and the Children’s Investment
Fund Foundation (CIFF) have created incentives for the
investment in pediatric ART formulation development [49–
51]. These efforts must be sustained and similar incentives
created to fund research anddevelopment of needed pediatric
medications.
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3.4. Pharmacokinetics and Development Challenges When
Designing Innovative Formulations. Pharmacokinetics, tox-
icity, and delivery preferences for pediatric medications
can differ greatly from adult medications, requiring specific
research to evaluate the safety and efficacy of pediatric
medications [52, 53]. This research often goes undone since
developing child-friendly medications is a challenging and
lengthy process that requires ensuring quality, safety, and
efficacy. Pharmacokinetic properties can vary according to
age and weight, which requires new drug formulations to
have flexible dosages [52, 54]. Palatability is a very important
factor when developing innovativemedications, but additives
can cause toxicity or change the pharmacokinetics of certain
medications [55–57]. Developing critical innovations for
certain populations, such as liquid formulations of FDCs,
can be limited for certain compounds that are large or
insoluble molecules or can run into dosing challenges when
the compounds do not have similar scaling as the child
moves across weight bands. Combinations may also result
in further pharmacokinetics challenges produced by their
own interactions. The extensive research required to ensure
the safety of new medications can deter researchers and
investigators from studying new and innovative pediatric
antiretroviral medications; however, many of the innova-
tions currently being studied show promising results [58–
61].
3.5. Psychosocial Factors That Influence Adherence. In addi-
tion to lack of pediatric formulations, there are many other
factors that influence adherence to ART. Medication proper-
ties that influence adherence include poor palatability, large
pill size, regimen complexity, and short dosing intervals,
but these properties are only encountered if the child is
given the opportunity to take the medication. Stigma, lack of
medical literacy, disclosure status of the child, child-caregiver
relationship, and high costs of HIV medications also prevent
children from receiving treatment or being compliant [5].
Even after developing new pediatric formulations, these
causes of poor adherence will still remain. Despite these
additional barriers, it is important to increase the number
of child-friendly antiretroviral drugs. Increasing the available
options for ART will diminish one of the compounding
factors for poor adherence.
4. Benefits of Child-Friendly ART
4.1. Increased Adherence. The link between adherence and
formulation properties is themost poignant argument for the
development of child-friendly ART.Many studies show a sig-
nificant connection between adherence and ART attributes
such as palatability, pill size, pill burden, short dosing inter-
vals, and regimen complexity. Over 21% of caregivers in a
South African study reported difficulties giving medication
due to poor palatability [12]. In Italy, a similar study found
that 38% of caregivers reported trouble administering ART
due to palatability and pill size [62]. A study of 119 children
with HIV in Canada demonstrated that 1/3 of participants
failed to adhere to the medication regimen due to palatability
[63]. Numerous studies, such as these, report that current
ART formulations worsen adherence [64–67].
The significant impact that HIVmedication formulations
have on adherence has led to the study of alternatives and
new formulations to help with medication administration
in children. Studies have looked at how to decrease poor
palatability by adding flavoring and creating pH-sensitive
microparticles to hide the bitter taste of many ARTs. A
study in Thailand examined the addition of a flavoring
agent to generic ART, using FLAVORx, whose ingredients
include a flavoring agent, propylene glycol, ethyl alcohol,
water, and triacetin, in ten different flavors: strawberry,
orange, banana, grapes, bubble gum, watermelon, lemon,
cherry, vanilla, and chocolate [31]. They found that 80% of
caregivers reported easiermedication dosing to children with
the flavoring addition, and the most popular flavors in this
study were strawberry, orange, and grape [31]. Another study
loaded indinavir into pH-sensitivemicroparticles, preventing
children from experiencing the bitter taste of the protease
inhibitor [59]. Researchers in another study mixed flavor-
ing into liquid EFV, with an aim to decrease the burning
mouth syndrome suffered by many children who use this
medication in liquid form. The study found that these new
flavored formulations decreased burningmouth syndrome in
healthy adult volunteers [60]. A separate study evaluated the
effectiveness of amilk-based powder formulation of ritonavir
to ease administration to infants and children. It found that
casein micelles, a milk protein, are an efficient carrier system
of ritonavir and serve to decrease bitter taste [68].
In addition to manipulating taste, other innovators have
been studying the impact of different modes of admin-
istration. These modes include sachets that deliver liquid
or gel ART all at once, sprinkles and nanoparticles that
allow caregivers to mix medications with food or liquids,
and dissolvable tablets that can be incorporated into fluids.
Nanotechnologies have been used to administer insoluble
LPV/r in sprinkles or sachet formulations and have shown
stability and good bioavailability [58]. Two articles studied
the effectiveness of novel sprinkle formulations of LPV/r and
efavirenz (EFV) [66, 69]. One study of sprinkle use inUganda
found that over 70%of the participants in two of three cohorts
chose to continue sprinkle formulations over liquid formula-
tions after an 8-week trial [69]. Sprinkles have been found to
improve tolerability of first-line ART in children and reduce
the cost to treatHIV-positive children [16]. Scored dispersible
lamivudine/stavudine combination tabs have been shown
to be cost-effective and easier to administer by caregivers
[70]. In addition, Drugs for Neglected Diseases Initiative and
Cipla joined to devise a sprinkle and 4-in-1 sachet to ease
delivery of ART in children [49]. The recent development
of ART-delivering sachets developed by Pratt School of
Engineering at Duke University has reduced the number
of perinatal HIV infections among infants in Ecuador [71].
Similar innovations can be used to deliverART to infantswith
HIV.
Because fixed-dose combinations and once-a-day formu-
lations are associated with better adherence, innovators have
also aimed to create innovative solutions for children to help
decrease pill burden. LPV/r, which has been recommended
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as first-line treatment by the WHO, has been combined with
abacavir/lamivudine or zidovudine/lamivudine in a study to
create a more tolerable, first-line, fixed-dose combination
for children [72]. Another study assessed the ability to
combine ritonavir and darunavir as a dry powder as a
second-line treatment for children [73]. A study aiming
to find a FDC effective in infants younger than 6 months
devised a FDC suppository with stavudine, lamivudine, and
nevirapine, which can ease administration in fussy infants
[74]. Nonetheless, few nonpill options are available in fixed-
dose combinations for infants and young children [27],
likely due to the previously discussed challenges with cost of
development and pharmacokinetics and dosing challenges.
In addition to FDC and once-a-day formulations, long-
acting formulations of ART, such as once-a-month injectable
antiretroviral and weekly ART infusions, are on the horizon
and could help children and adults who struggle with adher-
ence to daily therapy [75–77].Though injections can decrease
pill burden for children, cold-chain storage requirements for
injectable medications might pose similar barriers to those
for liquid medications in resource-limited settings. On the
other hand, the potential for not only improving ART adher-
ence but also exploring attempts to synchronize injectable
antiretrovirals with long-acting injections for contraception
could be particularly interesting for adolescent females.
Increased adherence in children with HIV has benefits
for both the child and the larger HIV-positive community.
Proper adherence leads to sufficient viral suppression, which
leads to longer and healthier lives for children living with
HIV. In addition, proper adherence reduces viral resistance
[78]. Viral resistance can be devastating in the community,
requiring individuals to change to a different ART, exhausting
the available medications. It is therefore imperative to intro-
duce new and innovative therapeutic options for children to
increase adherence and decrease viral resistance.
4.2. Easier Dosing for Caregivers. In addition to better
adherence in children, pediatric formulations of ART have
the possibility of reducing the time and energy investment
required of caregivers to administer medication to their
children. Many studies have reported that a significant cause
of nonadherence is child refusal [18, 79].The struggle between
child and caregiver can be taxing for elderly caregivers and
singlemother and fathers. Innovations such as taste-masking,
sprinkles, or injectable, long-acting agents could help ease the
struggle between caregivers and the children for whom they
care.
Concealing and hiding medications on the go is impor-
tant for both caregivers and children as a way to reduce
stigma and bullying. Sachets, such as the Pratt Pack created by
Duke University, can ease transportation of medications and
aid caregivers in concealing medications [71]. As discussed
previously, liquid medications can be easily spilled and
time-consuming for caregivers to measure out for dosing;
innovations such as sprinkles, dissolvable tablets, and sachets
can reduce the mess and time it takes to prepare medications.
Therefore, the development of child-friendly formulations
would be beneficial for children and their caregivers.
5. Future of Pediatric Antiretroviral Therapy
Despite many innovations, pediatric formulations are still
very limited in comparison to the number of adult formu-
lations [80, 81]. Without adequate or convenient pediatric
formulations, prescribers and caregivers resort to cutting,
crushing, or substituting adult medications to meet the need
for easier administration of medications for children [26, 32,
38, 61]. This can have drastic, negative impacts on children,
leading to over- or underdosing [82].
The pediatric market for ART is not a small version of
the adult market, but rather a unique niche which requires
developers to consider different routes and methods of
administration, different strengths, and a variety of flavors
[40, 83]. Fixed-dose combinations and once-a-day medica-
tions have solved many issues of adherence in older children
and adolescents who are able to swallow pills. For infants and
young children, there is still a lack of accessible formulations.
This results in poor adherence, viral resistance, and decreased
survival of HIV-positive children.
Many organizations, including UNITAID, Drugs for
Neglected Diseases initiative (DNDi), Medicines Patent Pool
(MPP), Clinton Health Access Initiative, President’s Emer-
gency Plan for AIDS Relief, and Elizabeth Glaser Pedi-
atric AIDS Foundation, have called for the prioritization
of pharmaceutical companies to address the need for new
innovative formulations [84–87]. As the WHO aims to
eliminate pediatric transmission of HIV, it is important not to
neglect the 3.2 million children with HIV worldwide and the
countless children who require ART treatment during breast-
feeding to achieve WHO goals and prevent new child infec-
tions.
To improve the lack of pediatric formulations, the World
Health Organization launched the global campaign “Make
Medicines Child Size.” The case is even more critical in the
case of poverty-related diseases that mainly affect children in
poor countries, such as HIV [88]. Due to the large number of
children with HIV worldwide, the chronicity of the disease,
and the critical role of adherence to therapy, it is imperative to
provide child-friendlymedications to improve adherence and
therefore increase life expectancy and success of treatment in
HIV-positive children.
6. Conclusion
Over 3.2 million children worldwide are waiting for pediatric
formulations of antiretroviral drugs. To address this need,
innovations in pediatric formulations must strive towards
(1) safe and effective ART for children, (2) palatable and
easy-to-swallow medications, (3) fixed-dose combinations to
decrease pill burden, (4) once-a-day formulations to lengthen
dosing intervals, (5) medications that are easy to transport
and store, (6) formulations that are simple for caregivers to
administer, and (6) securing incentives to drive investments
in the development of these critical formulations. Investment
must be made in pediatric-friendly formulations, especially
for infants, toddlers, and young children, to allow this
generation to survive and thrive.
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